» Articles » PMID: 17472993

Changes in Priorities for Improvement in Patients with Rheumatoid Arthritis During 1 Year of Anti-tumour Necrosis Factor Treatment

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2007 May 3
PMID 17472993
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To examine priorities for health status improvement in patients with active rheumatoid arthritis (RA) during anti-tumour necrosis factor (TNF) treatment.

Methods: Data were used from 173 patients with RA starting treatment with TNF-blocking agents. Outcome measures included assessment of health status with the Arthritis Impact Measurement Scales 2 (AIMS2) at baseline and after 3 and 12 months. The AIMS2 contains a priority list from which patients are asked to select from 12 areas of health the 3 in which they would most like to see improvement.

Results: After 1 year of treatment, 10 out of 12 areas of health on the AIMS2 were significantly improved. The most commonly selected priorities for improvement at baseline were pain (88%), hand and finger function (57%), walking and bending (42%), mobility (33%), and work (29%). At group level, this priority ranking remained largely unchanged during treatment. After adjustment for multiple comparisons, only pain was selected significantly less often at 3 and 12 months (71% at both assessments). Within individual patients, however, priorities often changed. Changes in the priority of pain were related to the achieved level of patient-perceived pain and disease activity.

Conclusions: This study shows that, at the group level, patients' priorities for improvement are fairly stable during 12 months of anti-TNF therapy, despite major improvements in health status. Although pain reduction becomes somewhat less important, it remains the most commonly selected priority. In contrast, individual patient priorities are not stable over the course of treatment and appear to be associated with differences in disease state.

Citing Articles

Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study.

Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K Arthritis Rheumatol. 2024; 77(3):253-262.

PMID: 39308007 PMC: 11865685. DOI: 10.1002/art.43014.


Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.

Choy E, Bykerk V, Lee Y, van Hoogstraten H, Ford K, Praestgaard A Rheumatology (Oxford). 2022; 62(7):2386-2393.

PMID: 36413080 PMC: 10321097. DOI: 10.1093/rheumatology/keac659.


Pain Sensitization as a Potential Mediator of the Relationship Between Sleep Disturbance and Subsequent Pain in Rheumatoid Arthritis.

Song J, Muhammad L, Neogi T, Dunlop D, Wohlfahrt A, Bolster M Arthritis Care Res (Hoboken). 2022; 75(4):778-784.

PMID: 35358376 PMC: 10322649. DOI: 10.1002/acr.24888.


[Rheumatic diseases and neuropathic pain : Diagnosis and treatment].

Lassen J, Baron R Z Rheumatol. 2020; 80(3):226-233.

PMID: 33355701 DOI: 10.1007/s00393-020-00950-9.


Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.

Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H Arthritis Res Ther. 2020; 22(1):243.

PMID: 33059710 PMC: 7566034. DOI: 10.1186/s13075-020-02324-7.


References
1.
Minnock P, FitzGerald O, Bresnihan B . Quality of life, social support, and knowledge of disease in women with rheumatoid arthritis. Arthritis Rheum. 2003; 49(2):221-7. DOI: 10.1002/art.11001. View

2.
Chamberlain M, Buchanan J, Hanks H . The arthritic in an urban environment. Ann Rheum Dis. 1979; 38(1):51-6. PMC: 1000319. DOI: 10.1136/ard.38.1.51. View

3.
Meenan R, Yelin E, Nevitt M, EPSTEIN W . The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum. 1981; 24(3):544-9. DOI: 10.1002/art.1780240315. View

4.
Yelin E, Lubeck D, Holman H, Epstein W . The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol. 1987; 14(4):710-7. View

5.
Prevoo M, van t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44-8. DOI: 10.1002/art.1780380107. View